Stabilization of Prostate Cancer with Amanita phalloides: Intervals with 5-Alpha-Reductase Inhibitors and Melatonin to Circumvent Resistance: Case Report

Abstract

Aims: Amanita phalloides contains alpha-amanitin, inhibiting RNApolymeraseII. Due to overexpression of switch genes in tumor cells, RNApolymeraseII is used to full extent there. Partial inhibition with amanitin influences tumor cell - but not normal cell - activity. A patient with diagnosed prostate cancer was treated successfully for six years with Amanita alone, prostate specific antigen levels increased slowly. However, the necessary dose for stabilization of the level increased during this time. To circumvent further habituation or resistance, other therapeutics were applied in intervals. Presentation of Case: Inhibitors of 5-alpha-reductase were applied in intervals of pausing Amanita. They can further stabilize the prostate antigen level, but tumor cells became resistant to this drug after a few months. The patient suffered under severe side effects. Melatonin was applied in one interval together with Amanita. It shows no additional side effect, but no additional advantage for the patient occurs. Discussion and Conclusion: Amanita is the drug for long term stabilization of a tumor patient. Fast occurrence of resistance was never observed so far. 5-alpha-reductase inhibitors can be applied in shorter intervals, with speedy development of resistance. Melatonin has no advantageous effect for this patient. Consequent monitoring for all therapy steps is recommended.